With the rapid onset of game-changing injectable emicizumab [HEMLIBRA] therapy for hemophilia, coagulation laboratories face a new challenge. On the occasions when HEMLIBRA-treated hemophiliacs need factor VIII concentrate therapy, or if there is a desire to test for residual factor VIII, what means does the laboratory possess?
Mar 31, 2020 2:09pm
Mar 31, 2020 1:18pm
Our March, 2020 Quick Question, "How does your facility measure extended half-life factor VIII concentrate therapy?" drew 24 votes, reflecting the number of laboratories serving Hemophilia and Bleeding Disorders services worldwide. Here are the answers:
Mar 26, 2020 2:31pm
The Anticoagulation Forum conducted a webinar on Wednesday, March 25 entitled Management of Warfarin Patients Who Have Difficulty Getting INR
Mar 23, 2020 2:02pm
Today, March 23, 2020, the International Journal of Laboratory Hematology released a study describing the clinical efficacy attributes of PTT-based one-stage clotting assays and two-stage chromogenic assays for the extended half-life factor IX concentrate, Alprolix. Click or tap the citation for the open-access article. Thank you to Dr.